Amylin Pharmaceuticals, Inc. and Eli Lilly and Co. said this week that a new meta-analysis of clinical data for their diabetes drug Byetta indicates that the injection does not increase the risk of cardiovascular events. The drug makers will use the data to support a new once-weekly version of the medication amid closer scrutiny by the FDA for heart risks of diabetes drugs. However, other reports have raised concerns in the medical community that Byetta side effects may increase the risk of p begun demanding more rigorous safety testing of diabetes drugs since a 2007 analysis suggested GlaxoSmithKline's blockbuster pill Avandia could increase heart risks. In December the agency issued new guidelines for testing potential heart problems with begun demanding more rigorous safety testing of diabetes drugs since a 2007 analysis suggested GlaxoSmithKline's blockbuster pill Avandia could increase heart risks. In December the agency issued new guidelines for testing potential heart problems with
No comments:
Post a Comment